Linezolid contributed to Clostridium difficile colitis with fatal outcome

Infection

Volumn 33, Issue 3, 2005, Pages 155-157

  Zabel, L T ^a   Worm, S ^a  

^a KLINIK AM EICHERT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; METRONIDAZOLE; RIFAMPICIN;

ACUTE ABDOMEN; ADULT; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ANURIA; ARTICLE; BLOOD CULTURE; CASE REPORT; CAUSE OF DEATH; CLAVICLE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; COLITIS; DEBRIDEMENT; DETERIORATION; DIARRHEA; DRUG FATALITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY; FECES; FECES CULTURE; HOSPITALIZATION; HUMAN; HYPOTENSION; INTERVERTEBRAL DISK DEGENERATION; ISCHEMIC HEART DISEASE; LABORATORY TEST; LEUKOCYTOSIS; LONG TERM CARE; MALE; MELENA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MULTIPLE ORGAN FAILURE; OSTEOMYELITIS; PARAPLEGIA; PSEUDOMEMBRANOUS COLITIS; RELAPSE; SEPSIS; SPINE STABILIZATION; TACHYCARDIA; TREATMENT INDICATION;

ACETAMIDES; ANTI-INFECTIVE AGENTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES;

EID: 21144432156     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-4112-6     Document Type: Article

References (12)

1. Moise PA, Forrest A, Birmingham MC, Schentag JJ: The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50: 1017-1026.
2. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ: Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-168.
3. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ: Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004; 32: 8-14.
4. French G: Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51 (Suppl. 2): 1145-1153.
5. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J: Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47: 1824-1831.
6. Wistrom J, Norrby SR, Myhre EB, Eriksson S, Granstrom G, Lagergren L, Englund G, Nord CE, Svenungsson B: Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 43-50.
7. Lazzarini L, De Lalla F: Failure of intravenous linezolid to treat Clostridium difficile associated diarrhea. J Chemother 2003; 15: 299-300.
8. Lode H, Von der Hoh N, Ziege S, Borner K, Nord CE: Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 2001; 33: 899-903.
9. Slatter JC, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, Johnson MG, Sanders PE, Hauer MJ, Fagerness PE, Stryd RP, Peng GW, Shobe EM: Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of drug. Metab Dispos 2001; 29: 1136-1145.
10. Peláez T, Alonso R, Pérez C, Alcalá L, Cuevas O, Bouza E: In vitro activity of linezolid against Clostridium difficile. Antimicrob Agents Chemother 2002; 46: 1617-1618.
11. Philips I, Baquero F, Bryskier A, Goldstein F, Mouton J, Schito G, Sidorenko S, Wiedeman B and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Linezolid breakpoints. Clin Microbiol Infect 2000; 7: 283-284.
12. MacGowan AC: Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 2003; 51 (Suppl. 2): II17-II25.